Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2008
11/20/2008US20080287484 Neurotrophin antagonist compositions
11/20/2008US20080287478 Nociceptin Analogues and Uses Thereof
11/20/2008US20080287466 4-amino-2,3-disubstituted thieno [2,3,d]pyrimidines and pharmaceutical compositions thereof
11/20/2008US20080287464 Depot Formulations
11/20/2008US20080287462 New compounds 834
11/20/2008US20080287456 Oral Therapeutic Compound Delivery System
11/20/2008US20080287455 Sulfanyl substituted phenyl methanones
11/20/2008US20080287454 Cxcr4 antagonists
11/20/2008US20080287451 Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
11/20/2008US20080287450 Novel Substituted Tetracyclic Tetahydrofuran, Pyrrolidine And Tetrahydrothiophene Derivatives
11/20/2008US20080287447 Methods for preparing eszopiclone
11/20/2008US20080287444 Pyrazole compounds useful as protein kinase inhibitors
11/20/2008US20080287438 Agent for preventing or treating neuropathy
11/20/2008US20080287430 Furan Compounds Useful As Ep1 Receptor Antagonists
11/20/2008US20080287424 e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome
11/20/2008US20080287423 Antidiabetic agents; neurodegenerative disorders; mixture with immunosuppresants
11/20/2008US20080287422 [9-(2,2-Dimethyl-propyl)-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza-(S)-cyclohepta[e]inden-7-yl]-acetic acid methyl ester; calcitonin gene-related peptide (CGRP) receptor antagonist; analgesic, antiinflammatory agent; migraine, neurogenic vasodilation, circulatory shock, menopause, asthma
11/20/2008US20080287418 Extended Release Compositions and Methods for Their Manufacture
11/20/2008US20080287415 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
11/20/2008US20080287406 Compositions and methods for treating medical conditions
11/20/2008US20080287399 Substituted Aminopyridines and Uses Thereof
11/20/2008US20080287398 Cold menthol receptor-1 antagonists
11/20/2008US20080287397 Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group
11/20/2008US20080287390 Pyrazolidinol compounds
11/20/2008US20080287385 Inhibitor oligonucleotides and their use for specific repression of a gene
11/20/2008US20080287375 Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof
11/20/2008US20080287355 Amylin and Amylin Agonists For Treating Psychiatric Diseases and Disorders
11/20/2008US20080287354 Pure polypeptides, neural prosaposin receptor proteins; controlled release and liposome formulations; oral, topical, and injectable administration; Parkinson's and Alzheimer's Diseases, retinal neuropathy, amyotrophic lateral sclerosis
11/20/2008US20080287350 Aequorin-Containing Compositions and Methods of Using Same
11/20/2008US20080287348 Soluble Hybrid Prion Proteins And Their Use In The Diagnosis, Prevention And Treatment Of Transmissible Spongiform Encephalopathies
11/20/2008US20080286813 Antibody specific for mutant presenilin 1 and method of use thereof
11/20/2008US20080286806 Ligand for G-protein coupled receptor GPR43 and uses thereof
11/20/2008US20080286394 Novel herbal formulation as brain tonic
11/20/2008US20080286391 Method for preparing ginkgo extracts having a low content of 4'-O-methyl pyridoxine and/or biflavones
11/20/2008US20080286373 ziprasidone, ziprasidone hcl; mono, di or triglycerides of C12-24 fatty acids, mono, or diesters of c12-c24 fatty acid and polyoxyethylene glycol, vitamin E tocopherol-succinic acid-polyethyleneglycol; sodium lauryl sulfate as anionic surfactant; hydroxyalkylalkyl cellulose; improved bioavailability;
11/20/2008US20080286368 administered sublingually in combination with a bio/mucoadhesion promoting compound (e.g. hydroxypropyl cellulose) in a manner giving rise to pharmacologically effective plasma levels of zolpidam, morphine, sufentanyl etc.within a short time after administration to treat pain, insomnia, diabetes etc
11/20/2008US20080286358 a nutraceutical tablet form for waking up energized in the morning containing an active ingredients adapted so that the user will wake up energized and refreshed, selected form thiamin, riboflavin, Niacin, B6, B12, eleuthero root extract, guarana seed extract and L-Tyrosine and a time release coating
11/20/2008US20080286344 Film to encapsulate pharmaceutical, agrochemical, detergent active ingredients; fill material less compacted than in a tablet but more than in a capsule; controlled release; fewer, lower quantities of excipients
11/20/2008US20080286343 Solid form
11/20/2008US20080286323 Human Therapeutic Cells Secreting Nerve Growth Factor
11/20/2008US20080286316 Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
11/20/2008US20080286267 Methods for treating nervous system inquiry and disease
11/20/2008US20080286263 Diagnosis Of Neurodegenerative Diseases
11/20/2008US20080286260 Diagnostic and Therapeutics for Diseases Associated with Peroxisome Proliferative Activated Receptor Alpha (Ppara)
11/20/2008US20080286258 Bifeprunox mesylate maintenance dose compositions and methods for using the same
11/20/2008US20080286250 Implantable Biocompatible Immunoisolatory Vehicle for Delivery of Gdnf
11/20/2008US20080286234 Method for treating demyelinating diseases
11/20/2008US20080286231 Novel inhibitors of glutaminyl cyclase
11/20/2008US20080286227 Use of Il-17F for the Treatment and/or Prevention of Neurologic Diseases
11/20/2008US20080286209 Comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, for use in treating (e.g., suppressing) alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety)
11/20/2008US20080286197 Antibody recognizing misfolded proteins that can be assigned specifically to one of the diseases
11/20/2008DE102007022790A1 Axomadol zur Schmerzbehandlung bei Arthrose Axomadol for pain management in osteoarthritis
11/20/2008CA2756796A1 Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives
11/20/2008CA2687254A1 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
11/20/2008CA2686926A1 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
11/20/2008CA2686754A1 Hetarylanilines as modulators for amyloid beta
11/20/2008CA2686394A1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
11/20/2008CA2686385A1 Dihydroquinone and dihydronaphthridine inhibitors of jnk
11/20/2008CA2686238A1 Antibody directed to g protein coupled receptors (gpcr)
11/20/2008CA2685570A1 Therapeutic compounds
11/20/2008CA2685460A1 A liquid formulation for administering nicotine
11/20/2008CA2685456A1 Coated oral nicotine formulation buffered with amino acid
11/20/2008CA2685452A1 Oral nicotine formulation buffered with amino acid
11/20/2008CA2685379A1 Axomadol for treating pain from arthritis
11/20/2008CA2684563A1 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists
11/20/2008CA2684404A1 Novel piperazine salts as d3/d2 antagonists
11/20/2008CA2683941A1 Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same
11/19/2008EP1992641A2 GLP-1 analogues
11/19/2008EP1992639A1 Peptide vaccine for inducing production of anti-amyloid- -peptide antibody
11/19/2008EP1992625A1 Arylamide pyrimidone compounds
11/19/2008EP1992624A1 Heteroarylamide pyrimidone compounds
11/19/2008EP1992621A1 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
11/19/2008EP1992620A1 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
11/19/2008EP1992618A1 Polycyclic cinnamide derivative
11/19/2008EP1992359A1 Neurotropic virus transport
11/19/2008EP1992357A1 Botulinum toxin treatments of neurological and neuropsychiatric disorders
11/19/2008EP1992349A1 CGRP antagonists, their preparation and use as a medicament
11/19/2008EP1992348A1 Pharmaceutical combination
11/19/2008EP1992342A1 Minimizing adverse experience associated with oxybutynin therapy
11/19/2008EP1992335A1 Spray drying methods and compositions thereof
11/19/2008EP1991869A2 Methods for the diagnosis of proliferative and/or conformational diseases
11/19/2008EP1991551A1 Meridamycin analogues for the treatment of neurodegenerative disorders
11/19/2008EP1991541A2 Novel pyrone-indole derivatives and process for their preparation
11/19/2008EP1991540A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors
11/19/2008EP1991539A1 New salts of an indole derivative and their use in medicine
11/19/2008EP1991531A1 Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
11/19/2008EP1991526A1 Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (pbr)
11/19/2008EP1991516A2 Hydroxylated long-chain resveratrol derivatives useful as neurotrophic agents
11/19/2008EP1991252A2 Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
11/19/2008EP1991251A1 Use of tlr3 agonists for the treatment of neurodegenerative disorders
11/19/2008EP1991234A2 Compositions and methods for the administration psychotropic drugs which modulate body weight
11/19/2008EP1991233A2 Hydroxypiperidine derivatives and uses thereof
11/19/2008EP1991214A2 Use of rasagiline for the treatment of multiple system atrophy
11/19/2008EP1931661B1 Isoxazolo derivatives as gaba a alpha5 inverse agonists
11/19/2008EP1509232B1 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
11/19/2008EP1478636B1 Amorphous citalopram
11/19/2008EP1453539B1 Immunotherapeutic methods and systems
11/19/2008EP1448545B1 Nf-kb inhibitors
11/19/2008EP1417349B1 Novel molecular target for neurotoxicity
11/19/2008EP1358213B1 Humanized antibodies that recognize beta amyloid peptide
1 ... 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 ... 1833